International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
diagnosis result
—امتیاز
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Pre-PMF Diagnosed0–0
  • Overt PMF Diagnosed1–1
  • PMF Not Diagnosed2–2
Direct Clinical Answer

The International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include bone marrow megakaryocytic proliferation. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Diagnoses primary myelofibrosis according to the International Consensus Classification (ICC) criteria published in 2022. This systematic diagnostic framework distinguishes between prefibrotic (early) and overt (fibrotic) stages of primary myelofibrosis using morphological, genetic, and clinical criteria. The ICC criteria refine the WHO classification system by providing better diagnostic specificity for myeloproliferative neoplasms. The diagnosis requires all three major criteria plus at least one minor criterion, confirmed in two consecutive determinations. This classification facilitates accurate diagnosis, appropriate staging, prognostic assessment, and treatment planning for patients with suspected primary myelofibrosis. The tool is particularly valuable for hematologists and pathologists in differentiating PMF from other myeloproliferative neoplasms and establishing precise diagnostic categorization.

Clinical Indication

The International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF) is indicated for bedside clinical practice to support Diagnoses primary myelofibrosis according to the International Consensus Classification (ICC) criteria published in 2022. This systematic diagnostic framework distinguishes between prefibrotic (early) and overt (fibrotic) stages of primary myelofibrosis using morphological, genetic, and clinical criteria. The ICC criteria refine the WHO classification system by providing better diagnostic specificity for myeloproliferative neoplasms. The diagnosis requires all three major criteria plus at least one minor criterion, confirmed in two consecutive determinations. This classification facilitates accurate diagnosis, appropriate staging, prognostic assessment, and treatment planning for patients with suspected primary myelofibrosis. The tool is particularly valuable for hematologists and pathologists in differentiating PMF from other myeloproliferative neoplasms and establishing precise diagnostic categorization.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Exclude reactive causes: infection, autoimmune disorders, metastatic cancer, drug-induced.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Genetic testing should use high-sensitivity assays (VAF ≥1%) for JAK2, CALR, and MPL mutations.

Formula & Variables:

Diagnosis requires ALL 3 major criteria (megakaryocytic proliferation, genetic clonality, exclusion of other MPNs) + ≥1 minor criterion (anemia, leukocytosis, splenomegaly, elevated LDH). Stage determined by fibrosis grade: Pre-PMF (grade 0-1), Overt PMF (grade 2-3).

Input Parameters

NameTypeRequiredDescription
bone_marrow_megakaryocytic_proliferationstringYesPresence of megakaryocytic proliferation and atypia on bone marrow biopsy
bone_marrow_fibrosis_gradestringYesBone marrow reticulin and/or collagen fibrosis grade (WHO grading scale)(grade)
genetic_mutation_presentstringYesPresence of JAK2, CALR, or MPL mutation, or another clonal genetic marker
reactive_fibrosis_excludedstringYesReactive bone marrow fibrosis due to infection, autoimmune disorder, or other cause excluded
other_mpn_excludedstringYesEssential thrombocythemia, polycythemia vera, BCR::ABL1-positive CML, myelodysplastic syndromes, and other myeloid neoplasms excluded
anemia_presentstringYesAnemia not attributable to comorbid conditions (minor criterion)
leukocytosis_presentstringYesLeukocytosis ≥11 × 10^9/L (minor criterion)
splenomegaly_presentstringYesPalpable splenomegaly on physical examination (minor criterion)
elevated_ldhstringYesLactate dehydrogenase above institutional reference range (minor criterion)

Score Interpretation & Guidance

RangeStageDescription
0–0Pre-PMF DiagnosedPrefibrotic Primary Myelofibrosis
1–1Overt PMF DiagnosedOvert Fibrotic Primary Myelofibrosis
2–2PMF Not DiagnosedDiagnostic Criteria Not Met

Evidence-Based References (EBM)

  • Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.DOI: 10.1182/blood.2022015850
  • Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 Oct 16;124(16):2507-13. doi: 10.1182/blood-2014-05-579136.DOI: 10.1182/blood-2014-05-579136
  • Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 15;8(2):15. doi: 10.1038/s41408-018-0054-y.DOI: 10.1038/s41408-018-0054-y

Related calculators